Liwei Wang

Dr. Liwei Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ZHZi Hui
Zi Hui
HWHao Wen
Hao Wen
JZJunlong Zhu
Junlong Zhu
HDHaowen Deng
Haowen Deng
XJXiaoying Jiang
Xiaoying Jiang
Renren BaiRenren Bai
Renren Bai

19 May 2022 in Topics in Current Chemistry
Verified
Journal Article
Closed access
PDF file
YGYuan Gao
Yuan Gao
SJSongwei Jiang
Songwei Jiang
NMNian-Dong Mao
Nian-Dong Mao
HXHuan Xiang
Huan Xiang
JDJi-Long Duan
Ji-Long Duan
TXTian Xie
Tian Xie

4 September 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JLJunjie Li
Junjie Li
RZRui Zhao
Rui Zhao
PMPeiran Miao
Peiran Miao
FXFengfeng Xu
Fengfeng Xu
JCJiahao Chen
Jiahao Chen
Renren BaiRenren Bai
Renren Bai

12 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LWLiwei Wang
Liwei Wang
SJSongwei Jiang
Songwei Jiang
YYYing-Hui Yuan
Ying-Hui Yuan
JDJilong Duan
Jilong Duan
NMNian-Dong Mao
Nian-Dong Mao
XYXiang-Yang Ye
Xiang-Yang Ye
As one of the key phosphatidylinositol 3-kinase-related kinases (PIKKs) family members, ataxia telangiectasia and RAD3-related protein kinase (ATR) is crucial in maintaining mammalian cell genomic integrity in DNA damage response (DDR) and repair pathways. Dysregulation of ATR has been found across different cancer types. In recent years, the inhibition of ATR has been proven to be effective in cancer therapy in preclinical and clinical studies. Importantly, tumor-specific alterations such as ATM loss and Cyclin E1 (CCNE1) amplification are more sensitive to ATR inhibition and are being exploited in synthetic lethality (SL) strategy. Besides SL, synergistic anticancer effects involving ATRi have been reported in an increasing number in recent years. This review focuses on the recent advances in different forms of synergistic antitumor effects, summarizes the pharmacological benefits and ongoing clinical trials behind the biological mechanism, and provides perspectives for future challenges and opportunities. The hope is to draw awareness to the community that targeting ATR should have great potential in developing effective anticancer medicines.

25 January 2024 in Molecules
Verified
Journal Article
Open access
PDF file
BSBo-Wen Sun
Bo-Wen Sun
PZPeng-Peng Zhang
Peng-Peng Zhang
ZWZong-Hao Wang
Zong-Hao Wang
XYXia Yao
Xia Yao
MHMeng-Lan He
Meng-Lan He
LWLiwei Wang
Liwei Wang
Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.

6 September 2022 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
YGYuan Gao
Yuan Gao
NMNian-Dong Mao
Nian-Dong Mao
HCHao Che
Hao Che
LXLi Xu
Li Xu
Renren BaiRenren Bai
Renren Bai
TXTian Xie
Tian Xie
A series of novel N-alkyl-N-hydroxyl carboximates derived from β-elemene were fortuitously discovered. Most of them showed more potent anti-proliferative activities than their lead compound β-elemene (1). Notably, compound 11i exhibited significant inhibitory effects on the proliferation of three lung cell lines (H1975, A549 and H460) and several other tumour cell lines (H1299, U87MG, MV4-11, and SU-DHL-2). Preliminary mechanistic studies revealed that compound 11i could significantly induce cell apoptosis. Further in vivo study in the H460 xenograft mouse model validated the anti-tumour activities of 11i with a greater tumour growth inhibition (TGI, 68.3%) than β-elemene and SAHA (50.1% and 55.9% respectively) at 60 mg/kg ip dosing, without obvious body weight loss and toxicity. Thus, such N-alkyl-N-hydroxyl carboximate class of compounds exemplified as 11i demonstrated potent anticancer activities both in vitro and in vivo, and should warrant further investigation for potential anticancer therapy. Graphical Abstract